mCRPC in focus
Transcript: The continuing need for improved mCRPC treatments
Professor Karim Fizazi
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, I guess, prostate cancer remains a very important disease. Many men will get it, probably one out of eight men or so in Western countries.
Fortunately enough, not so many men will die from it, but still it remains a big killer, probably a number two or three cancer killer in many Western countries. In France, my country for example, unfortunately, approximately 8,000 men die from the disease every year.
So this remains very significant, not even speaking about the morbidity many of the men suffer from. So I think it remains key to improve all the treatments for these men.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.